iECURE to Present Preliminary Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at the ASGCT and SIMD Annual Meetings
Go back to iECURE to Present Preliminary Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at the ASGCT and SIMD Annual Meetings| (NASDAQ: DTIL) | Delayed: 7.08 +0.27 (3.96%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.81 | 52 Week High | $ | |||
| Open | $6.95 | 52 Week Low | $ | |||
| Day High | $7.20 | P/E | N/A | |||
| Day Low | $6.88 | EPS | $ | |||
| Volume | 402,857 | |||||
